Xilong Scientific Co., Ltd. (SHE:002584)
China · Delayed Price · Currency is CNY 8.93
-0.19 (-2.08%)
Jul 10, 2026, 1:55 PM CST
Xilong Scientific Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 7,421 | 7,322 | 7,803 | 7,078 | 6,176 | 5,372 |
Other Revenue | 8.83 | 8.83 | 13.86 | 13.73 | 7.27 | 8.12 |
| 7,430 | 7,331 | 7,816 | 7,092 | 6,183 | 5,380 | |
Revenue Growth (YoY) | -2.31% | -6.21% | 10.22% | 14.69% | 14.93% | -13.83% |
Cost of Revenue | 6,896 | 6,822 | 7,294 | 6,632 | 5,756 | 4,856 |
Gross Profit | 533.22 | 508.43 | 522.88 | 459.7 | 426.78 | 523.64 |
Selling, General & Admin | 275.24 | 266.42 | 243.65 | 234.82 | 211.47 | 240.76 |
Research & Development | 84.48 | 88.31 | 109.9 | 95.7 | 90.47 | 118.97 |
Other Operating Expenses | 8.97 | 1.62 | -3.54 | 5.75 | 17.19 | 16.02 |
Operating Expenses | 400.33 | 384.86 | 361.49 | 344.61 | 331.92 | 395.75 |
Operating Income | 132.89 | 123.57 | 161.39 | 115.1 | 94.86 | 127.88 |
Interest Expense | -53.59 | -48.64 | -46.21 | -60.86 | -49.08 | -67.5 |
Interest & Investment Income | 5.76 | 5.59 | 5.38 | 6.7 | 92.1 | 144.18 |
Currency Exchange Gain (Loss) | -2.27 | -2.27 | -3.25 | -4.38 | -9.5 | 1.3 |
Other Non Operating Income (Expenses) | 0.11 | -3.82 | -28.17 | -13.96 | -29.59 | -7.76 |
EBT Excluding Unusual Items | 86.25 | 74.43 | 89.15 | 42.6 | 98.79 | 198.11 |
Impairment of Goodwill | - | - | - | -6.54 | - | - |
Gain (Loss) on Sale of Investments | -10.8 | -10.8 | - | - | 0 | - |
Gain (Loss) on Sale of Assets | -0.45 | -0.45 | -0.82 | 0.21 | -0.14 | -0.39 |
Asset Writedown | -3.75 | -0.16 | -6.32 | -0.5 | -1.47 | 0.34 |
Other Unusual Items | -132.5 | -132.07 | -9.72 | 7.15 | 5.57 | 11.04 |
Pretax Income | -61.24 | -69.06 | 72.29 | 42.92 | 102.74 | 209.1 |
Income Tax Expense | 9.99 | 5.33 | 9.3 | 8.33 | 15.04 | 7.98 |
Earnings From Continuing Operations | -71.23 | -74.39 | 62.99 | 34.59 | 87.69 | 201.12 |
Minority Interest in Earnings | -0.92 | -1.1 | -1.22 | -1.24 | 1.37 | -14.06 |
Net Income | -72.15 | -75.49 | 61.77 | 33.35 | 89.06 | 187.06 |
Net Income to Common | -72.15 | -75.49 | 61.77 | 33.35 | 89.06 | 187.06 |
Net Income Growth | - | - | 85.24% | -62.56% | -52.39% | 228.91% |
Shares Outstanding (Basic) | 514 | 581 | 562 | 556 | 594 | 534 |
Shares Outstanding (Diluted) | 514 | 581 | 562 | 556 | 594 | 534 |
Shares Change (YoY) | -14.45% | 3.40% | 1.04% | -6.39% | 11.09% | -6.02% |
EPS (Basic) | -0.14 | -0.13 | -0.11 | 0.06 | 0.15 | 0.35 |
EPS (Diluted) | -0.14 | -0.13 | -0.11 | 0.06 | 0.15 | 0.35 |
EPS Growth | - | - | - | -60.00% | -57.14% | 250.00% |
Free Cash Flow | -343.85 | -30.75 | 257.23 | -499.96 | -514.59 | 316.27 |
Free Cash Flow Per Share | -0.67 | -0.05 | 0.46 | -0.90 | -0.87 | 0.59 |
Dividend Per Share | - | - | 0.033 | 0.020 | - | - |
Dividend Growth | - | - | 65.00% | - | - | - |
Gross Margin | 7.18% | 6.94% | 6.69% | 6.48% | 6.90% | 9.73% |
Operating Margin | 1.79% | 1.69% | 2.07% | 1.62% | 1.53% | 2.38% |
Profit Margin | -0.97% | -1.03% | 0.79% | 0.47% | 1.44% | 3.48% |
Free Cash Flow Margin | -4.63% | -0.42% | 3.29% | -7.05% | -8.32% | 5.88% |
EBITDA | 197.65 | 184.96 | 209.28 | 155.22 | 130.97 | 157.56 |
EBITDA Margin | 2.66% | 2.52% | 2.68% | 2.19% | 2.12% | 2.93% |
D&A For EBITDA | 64.76 | 61.39 | 47.88 | 40.13 | 36.11 | 29.68 |
EBIT | 132.89 | 123.57 | 161.39 | 115.1 | 94.86 | 127.88 |
EBIT Margin | 1.79% | 1.69% | 2.07% | 1.62% | 1.53% | 2.38% |
Effective Tax Rate | - | - | 12.86% | 19.41% | 14.64% | 3.82% |
Revenue as Reported | 7,430 | 7,331 | 7,816 | 7,092 | 6,183 | 5,380 |
Advertising Expenses | - | 0.21 | 3.85 | 0.39 | 3.73 | 0.97 |